How Health Technology Assessment Agencies View Clinical Evidence for Tumor Agnostic Therapies

ISPOR Europe 2022 -- Traditionally, tumors have been treated based on their site of origin rather than their specific characteristics. Recent advances in powerful technologies that allow for a more rapid and accurate understanding of tumor biology have led to the development of tumor agnostic therapies, which target unique genetic molecular features of the tumor. Since health technology assessment (HTA) agencies play a key role in patient access to therapies, it is important to consider the way in which they evaluate tumor agnostic therapies and how this differs from traditional cancer treatments. We set out to understand how HTA agencies critique and assess clinical and economic evidence submitted in support of tumor agnostic therapies (typically based on non-comparative basket trials), and how this influences their final decisions.